---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-033947"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:58:16.740257+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics FY23 net loss $96.0M; raises $287.5M; Phase 3 on track

## Summary
- FY 2023 net loss $96.0M ($2.25 diluted EPS) vs $89.1M ($3.35) prior year; no revenue.
- Cash $160.7M at Dec 31, 2023; subsequent $287.5M gross from Feb 2024 offering.
- Phase 2b 72-week data: sustained reductions in Gd-IgA1, hematuria, UPCR with stable eGFR; Phase 3 topline 1H 2025.
- Appointed Robert M. Brenner, M.D. as CMO and William D. Turner as CDO.

## SEC filing metadata
- accession: 0000950170-24-033947
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/0000950170-24-033947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/vera-20240320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-033947
- JSON: https://secwatch.observer/filing/0000950170-24-033947.json
- Plain text: https://secwatch.observer/filing/0000950170-24-033947.txt

## Key facts
- Earnings Releases
  Vera Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income a net loss of $96.0 million, or a net loss per diluted share of $2.25, EPS net loss per diluted share of $2.25.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: a net loss of $96.0 million, or a net loss per diluted share of $2.25
  - EPS: net loss per diluted share of $2.25
  - Result: reported results
  source text: For the year ended December 31, 2023, the company reported a net loss of $96.0 million, or a net loss per diluted share of $2.25
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/0000950170-24-033947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.